Metastatic Hormone Refractory Prostate Cancer Completed Phase 3 Trials for Cabazitaxel (DB06772)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01254279Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing RegimenTreatment